The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

Regulators upheld their earlier decision after reexamination, saying the substance does not meet the criteria for new active ...

The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...

EU regulator says treatment could fill major gap for patients who lack a suitable stem cell donor and leads to sharp drops in ...

Karina Volkova trains in a clinic using a temporary permit that expires in 2027, giving her a narrow window to clear all ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

An analysis of a German multicentre study reveals that women are more likely than men to receive inappropriate diagnostic ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

With indications that ‘“dialysis begets dialysis”’ and can obscure kidney function improvement, a novel trial shows notable ...

In Parkinson’s disease, early signs such as constipation, loss of smell, and REM sleep disturbance may appear up to a decade ...

A new predictive tool combining amyloid PET data with key clinical factors estimates an individual’s lifetime risk for mild ...